- December 7, 2017
- Category: Press release
Cachan | Thursday, December 7th, 2017
DOSIsoft, leading provider of advanced software solutions for Radiation Therapy, and UNICANCER, which groups together all French Comprehensive Cancer Centers (FCCCs), announce a scientific partnership, aiming at bringing an innovative solution to optimize patient safety in Radiation Therapy. This R&D partnership is established under the framework of the “iNNOV’Up Experimentation” program, led by the French Paris Region and managed by public investment bank Bpifrance.
Accelerating transfer of new products towards clinical routine
DOSIsoft has developed a software solution, EPIbeam, that aims at evaluating before treatment the absorbed radiation dose which will be delivered to the patient. This software will complete the regulatory quality and safety controls, currently carried out on the linear accelerators, and thus will contribute to guarantee high-precision treatments for the patients with the latest generation of equipment. It allows to ensure before treatment that the absorbed delivered dose is identical to the planned absorbed dose (planned with the Treatment Planning System – TPS). The time allocated to treatment machine calibration measurements is also significantly reduced.
“This experimentation is an excellent means to accelerate transfer of new products to clinical routine, by sharing lessons learned, concrete use cases, usability of these new products, and also the remaining improvements to be implemented before a wider deployment of solutions on the market, including the international market.” welcomes Marc Uszynski, DOSIsoft CEO.
Providing in real-time usable and relevant data regarding treatment quality
“UNICANCER promotes a model for oncology based on multidisciplinarity, personalization of treatments and a research-to-care continuum… As a major player in patient care and research in oncology, our objective with this experimentation is to obtain an increase in quality for patient care in radiation therapy, while ensuring treatment safety for the patient.” said Christian Caillot, R&D Director of UNICANCER.
“In addition to the quality and safety procedures used by the medical teams, this software solution has the advantage of providing data in real-time regarding treatment quality, by connecting to the existing equipment and without any need for additional hardware investment. This experimentation is part of the scientific partnerships carried out along the Research and Development axes with the CLCCs and defined within the Global Radiation Therapy Offer of UNICANCER” underlines Luc Delporte, Purchasing Director of UNICANCER.
The conclusions of the experimentation are expected by the end of 2017. Beyond this partnership, DOSIsoft pursues its scientific collaborations with UNICANCER and all CLCCs for further improving patient care in radiation therapy.
Founded in 2002, DOSIsoft develops cutting-edge software solutions for Radiation Oncology and Nuclear Medicine. 15 years of innovation and R&D investments have led to world leading software solutions used successfully in over 160 hospital centers in 18 countries around the world. Spin-off of Gustave Roussy and Institut Curie, DOSIsoft constantly innovates in partnership with the major cancer institutes and research centers in the world.. www.dosisoft.com
UNICANCER groups together all the French Comprehensive Cancer Centres (FCCCs). These 20 private, non-profit health establishments are exclusively dedicated to care, research and education in cancer. UNICANCER also aims to facilitate the pooling of resources, expertise and best practice between FCCCs in the areas of research, care, hospital management, and procurement. Its mission is to enable FCCCs to stay ahead and innovate together, and always for the benefit of their patients.
As a clinical research sponsor, UNICANCER has shored up its position as a major French player in oncology. It is accredited by the Ministry of Health and is eligible for public grants. Its research unit is tasked with implementing UNICANCER’s overall research strategy, which involves promoting access to innovation and improving care for patients with cancer. In 2016, 5,400 patients were included in UNICANCER sponsored clinical trials within 270 healthcare establishments, 20% of which abroad.
The UNICANCER Translational Research and Development in Radiation Oncology (UNITRAD) Group’s goal is to promote innovative and strategic radiotherapy research programmes, and to develop collaborative networks. Its experts work on numerous of topics such as brachytherapy, imaging, modelling and radiomics, radiobiology and radiopotentiation, ionising radiation, quality assurance and methodology.
UNICANCER 2016 key figures: 20 healthcare establishments, 19,000 employees, €2.4 billion in revenue, more than 500 ongoing clinical trials, over 135,000 patients hospitalized per year. Financial volume negotiated by UNICANCER purchasing department: 475 million euros per year. For further information: UNICANCER’s 2016 activity report and www.unicancer.fr/en
About Paris Région Entreprises
Paris Region Enterprises is the agency in charge of promoting the Paris Region to attract international companies and support them in setting up providing a full range of tailored services, including a dedicated business advisor who enables international investors to:
- Assess their target markets and understand the business regulations
- Meet with key players and establish relationships with potential clients and partners
- Benefit from public support programs
- Launch their businesses by choosing the best legal structure, setting up their offices, recruiting the right staff and opening bank accounts
- Guide them through the various steps of relocating to and setting up in the Paris Region.
Paris Region Entreprises is supported by the Ile-de-France Regional Council. It is an active member of the “Enterprise Europe Network”.
UNICANCER: Gwendoline Miguel | Communication and Press Relations | +33 1 76 64 78 00 | email@example.com
DOSIsoft: Xiaolu Chen | +33 1 41 24 26 26 | firstname.lastname@example.org